CG Oncology Statistics

Total Valuation

CG Oncology has a market cap or net worth of $1.93 billion. The enterprise value is $1.25 billion.

Market Cap	1.93B
Enterprise Value	1.25B

Important Dates

The last earnings date was Tuesday, May 13, 2025, before market open.

Earnings Date	May 13, 2025
Ex-Dividend Date	n/a

Share Statistics

CG Oncology has 76.23 million shares outstanding. The number of shares has increased by 1,511.14% in one year.

Current Share Class	76.23M
Shares Outstanding	76.23M
Shares Change (YoY)	+1,511.14%
Shares Change (QoQ)	+10.33%
Owned by Insiders (%)	0.68%
Owned by Institutions (%)	89.97%
Float	61.13M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2,929.26
Forward PS	3,656.06
PB Ratio	2.76
P/TBV Ratio	2.75
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	1,890.90
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 30.97, with a Debt / Equity ratio of 0.00.

Current Ratio	30.97
Quick Ratio	30.42
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -16.57% and return on invested capital (ROIC) is -13.18%.

Return on Equity (ROE)	-16.57%
Return on Assets (ROA)	-12.85%
Return on Invested Capital (ROIC)	-13.18%
Return on Capital Employed (ROCE)	-19.05%
Revenue Per Employee	$5,858
Profits Per Employee	-$934,133
Employee Count	113
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -22.59% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-22.59%
50-Day Moving Average	23.75
200-Day Moving Average	30.51
Relative Strength Index (RSI)	52.43
Average Volume (20 Days)	1,493,875

Short Selling Information

The latest short interest is 11.22 million, so 14.72% of the outstanding shares have been sold short.

Short Interest	11.22M
Short Previous Month	9.09M
Short % of Shares Out	14.72%
Short % of Float	18.36%
Short Ratio (days to cover)	5.94

Income Statement

In the last 12 months, CG Oncology had revenue of $662,000 and -$105.56 million in losses. Loss per share was -$1.51.

Revenue	662,000
Gross Profit	-91.70M
Operating Income	-134.40M
Pretax Income	n/a
Net Income	-105.56M
EBITDA	-134.35M
EBIT	-134.40M
Loss Per Share	-$1.51

Full Income Statement

Balance Sheet

The company has $688.43 million in cash and $1.04 million in debt, giving a net cash position of $687.40 million or $9.02 per share.

Cash & Cash Equivalents	688.43M
Total Debt	1.04M
Net Cash	687.40M
Net Cash Per Share	$9.02
Equity (Book Value)	704.76M
Book Value Per Share	9.25
Working Capital	678.55M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$81.98 million and capital expenditures -$238,000, giving a free cash flow of -$82.22 million.

Operating Cash Flow	-81.98M
Capital Expenditures	-238,000
Free Cash Flow	-82.22M
FCF Per Share	-$1.08

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-20,302.27%
Pretax Margin	-15,945.17%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

CG Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1,511.14%
Shareholder Yield	-1,511.14%
Earnings Yield	-5.44%
FCF Yield	-4.24%

Analyst Forecast

The average price target for CG Oncology is $64.00, which is 152.77% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$64.00
Price Target Difference	152.77%
Analyst Consensus	Strong Buy
Analyst Count	10
Revenue Growth Forecast (5Y)	272.26%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CG Oncology has an Altman Z-Score of 58.65 and a Piotroski F-Score of 4.

Altman Z-Score	58.65
Piotroski F-Score	4